Ensign Peak Advisors
TRML

Ensign Peak Advisors’s Tourmaline Bio TRML Stock Holding History

Ensign Peak Advisors’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,283
Closed -$193K – 2351
2022
Q2 		$193K Sell
4,283
-472
-10% -$37.2K ﹤0.01% 1804
2022
Q1 		$468K Hold
4,755
– – ﹤0.01% 1576
2021
Q4 		$727K Buy
+4,755
New +$704K ﹤0.01% 1439

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's TRML Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Tourmaline Bio (TRML) in Q3 2022, closing a stake of 4,283 shares — an estimated $193K sold.

Ensign Peak Advisors first reported a position in TRML in Q4 2021 and held it in 3 quarters. The position peaked at $727K in Q4 2021. 56 funds tracked by Wall St. Rank hold TRML as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Tourmaline Bio position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 4,283 Tourmaline Bio shares in Q3 2022, an estimated $193K.
  • Ensign Peak Advisors first reported a position in Tourmaline Bio in Q4 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's Tourmaline Bio position peaked at $727K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.